Dr. Goy on Developments in the Field of Immunology

Andre Goy, MD
Published Online: Wednesday, Aug 14, 2013

Andre Goy, MD, Chairman and Director and Chief of Lymphoma at John Theurer Cancer Center, comments on the recent developments in fighting cancer with the immune system.

The effort to harness the immune system to fight cancers cells has had some success, though little has translated into lasting benefit. Recently, the development of immunology has focused on unleashing T cells and promoting their antitumor effect.

Immunology research has focused, among other things, on generating chimeric antigen T cells and developing monoclonal antibodies to unleash T cells. The oncology community, Goy says, believes that using the immune system is promising and could translate into great benefit for patients.

Andre Goy, MD, Chairman and Director and Chief of Lymphoma at John Theurer Cancer Center, comments on the recent developments in fighting cancer with the immune system.

The effort to harness the immune system to fight cancers cells has had some success, though little has translated into lasting benefit. Recently, the development of immunology has focused on unleashing T cells and promoting their antitumor effect.

Immunology research has focused, among other things, on generating chimeric antigen T cells and developing monoclonal antibodies to unleash T cells. The oncology community, Goy says, believes that using the immune system is promising and could translate into great benefit for patients.




View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Advances in™ Targeted Therapies: The Emerging Role of PI3K Inhibitors in the Treatment of Hematologic MalignanciesNov 16, 20171.5
Community Practice Connections™: The Emergence of CAR-T Cell Therapy for Hematologic Malignancies: Moving From Bench to BedsideDec 29, 20171.5
Publication Bottom Border
Border Publication
$emailPop$